摘要
糖尿病肾病(DKD)是慢性肾病(CKD)常见的形式,白蛋白尿则是CKD进展的重要标志物,在评估肾脏和(或)心血管疾病的疗效试验中白蛋白尿可作为一个治疗终点。但白蛋白排泄率短期个体变异性较大,是否有更方便、有效的替代方法?近期Diabetes Obes Metab杂志就这一问题发表了一篇题为《白蛋白尿变化作为糖尿病心血管和肾脏结局的替代终点》的综述[Palmer BF.Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes.Diabetes Obes Metab,2023,25(6):1434-1443]。该文为开放获取文章,本文对其进行了中文编译。该文指出,相对于24 h尿蛋白,随机尿的尿白蛋白/肌酐比值(UACR)更易于操作,可作为替代方法,但其也有一定局限性。本文还对糖尿病患者中白蛋白尿与心肾结局和常见替代标志物的关系进行综述,并对白蛋白尿的治疗策略作了讨论。
Diabetic kidney disease(DKD)is a common form of chronic kidney disease(CKD),and albuminuria is a crucial marker of CKD progression.In clinical trials evaluating the efficacy of treatments for kidney and/or cardiovascular diseases,albuminuria can serve as a treatment endpoint.However,due to the short-term variability in albumin excretion rate necessitates a more practical and effective alternative.A recent review"Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes"was published in Diabetes Obes Metab[Palmer BF.Diabetes Obes Metab,2023,25(6):1434-1443].This open-access article,now available in Chinese,explores the spot urinary albumin/creatinine ratio(UACR)as a more viable alternative to 24-hour urinary protein,despite the limitations.This article also reviews the relationship between albuminuria and cardiovascular and renal outcomes in diabetic patients,along with common alternative markers,and discusses the treatment strategies for albuminuria.
作者
本刊编辑部
CJEM Editorial Office
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2024年第4期350-355,共6页
Chinese Journal of Endocrinology and Metabolism
关键词
白蛋白尿
糖尿病
心血管疾病
慢性肾病
Albuminuria
Diabetes mellitus
Cardiovascular disease
Chronic kidney disease
